Medpace Holdings, Inc. splits its revenue into 6 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Oncology at $229.9 million, 32% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,838
|
716
|
707
|
707
|
708
|
660
|
603
|
559
|
537
|
| Oncology |
836
+16.2%
share 29.5%
|
230
+19.4%
share 32.1%
|
209
+11.0%
share 29.6%
|
201
+18.0%
share 28.5%
|
196
+16.5%
share 27.7%
|
193
share 29.2%
|
189
share 31.3%
|
170
share 30.5%
|
168
share 31.3%
|
| Metabolic |
916
+48.2%
share 32.3%
|
209
+5.0%
share 29.2%
|
—
|
238
+60.5%
share 33.6%
|
250
+103.3%
share 35.3%
|
199
share 30.2%
|
—
|
148
share 26.5%
|
123
share 22.9%
|
| Other |
380
-10.3%
share 13.4%
|
100
-6.1%
share 14.0%
|
—
|
—
|
88
-14.5%
share 12.5%
|
106
share 16.1%
|
118
share 19.6%
|
96
share 17.2%
|
103
share 19.2%
|
| Central Nervous System |
320
+38.6%
share 11.3%
|
84
+27.5%
share 11.7%
|
83
+35.5%
share 11.7%
|
80
+46.1%
share 11.4%
|
73
+48.7%
share 10.3%
|
66
share 9.9%
|
61
share 10.1%
|
55
share 9.8%
|
49
share 9.2%
|
| Cardiology |
241
+2.6%
share 8.5%
|
61
+3.3%
share 8.6%
|
60
+2.4%
share 8.5%
|
56
-3.5%
share 8.0%
|
63
+8.1%
share 8.9%
|
59
share 9.0%
|
59
share 9.7%
|
58
share 10.4%
|
58
share 10.9%
|
| Antiviral And Anti Infective |
146
+10.9%
share 5.1%
|
32
-12.9%
share 4.4%
|
38
+29.8%
share 5.3%
|
38
+22.4%
share 5.4%
|
38
+9.8%
share 5.4%
|
37
share 5.5%
|
29
share 4.8%
|
31
share 5.6%
|
35
share 6.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MEDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1668397
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.